Evolent Health Financial Results
Evolent Health reported Q3 2026 revenue of $725.4 million, a significant increase from $479.5 million in the prior year, driven by strong demand for complex specialty care solutions and oncology launches. The company also announced a four-year renewal of its largest Surgical Management contract and two new oncology service expansions with national payers.
“As health plan customers seek to balance affordability with patient and doctor experience, they continue to turn to Evolent by renewing agreements and in many cases, expanding the work they do with us. That growth and demand from existing clients, as well as strong execution in our 2026 oncology launches, continue to drive strong performance in 2026. Looking ahead, I believe our innovative AI platform and our oncology solution will drive growth and margin expansion for Evolent in the quarters to come.”
Seth Blackley, Co-Founder and Chief Executive Officer of Evolent